Duzyj Christina M, Einerson Brett D, Afshar Yalda, Fox Karin A, Saad Antonio F, Carusi Daniela A, Herrera Christina L, Lyell Deirdre J, Abuhamad Alfred Z, Farber Michaela K, Roberts Anne C, Hobson Sebastian R, Sentilhes Loic, Sibai Baha M, Matsuo Koji, Terlizzi Kristen, Shainker Scott A, Silver Robert M, Bartels Helena C, Shipp Thomas D, Huang Marilyn, Cahill Alison G, Wright Jason D, Saade George R, Longo Monica
Department of Obstetrics and Gynecology, Massachusetts General Hospital, the Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, the Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Brigham and Women's Hospital and Harvard Medical School, and the Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; the Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah; the Division of Maternal-Fetal Medicine, University of California, Los Angeles, and the Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, the Department of Obstetrics and Gynecology, Stanford School of Medicine, Stanford, the Department of Radiology, University of California, San Diego, La Jolla, and the National Accreta Foundation, Saratoga, California; the Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, the Department of Obstetrics and Gynecology, UT Southwestern Medical Center, Dallas, the Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at UTHealth Houston, and the Department of Women's Health, the University of Texas at Austin, Dell Medical School, Austin, Texas; the Department of Obstetrics & Gynecology, Inova Fairfax, Fairfax, the Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, and the Department of Obstetrics and Gynecology, Comprehensive Cancer Center, University of Virginia Health, Charlottesville, Virginia; the Department of Obstetrics & Gynaecology, University of Toronto, and the Division of Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; the Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France; the Department of Obstetrics and Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland; the Department of Obstetrics and Gynecology, Columbia University, New York, New York; and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.
Obstet Gynecol. 2025 Jun 1;145(6):581-585. doi: 10.1097/AOG.0000000000005929. Epub 2025 May 1.
Placenta accreta spectrum (PAS) disorder poses significant risks to maternal health, given the complexities of screening, diagnosis, and management. To address these challenges, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) hosted a workshop on June 10-11, 2024, bringing together expert health care professionals, researchers, stakeholders, and patient advocates to identify knowledge gaps, with an overarching goal of informing future research and best practices for PAS. Key discussions revolved around the resources and infrastructure needed to advance screening, diagnosis, and clinical management of PAS, alongside ways to enhance collaboration across disciplines. Participants considered strategies to optimize existing research resources and explored opportunities to strengthen partnerships between the NICHD and key stakeholders to achieve mutual objectives. The workshop-attended by representatives from the Society for Maternal-Fetal Medicine, the American College of Obstetricians and Gynecologists, the Pan-American Society for the Placenta Accreta Spectrum, the National Accreta Foundation, the American Institute of Ultrasound in Medicine, and the Society of Gynecologic Oncology-aimed to foster consensus on essential PAS topics and to identify clinical and research priorities in all phases of PAS care. Additionally, a critical focus of the workshop was to enhance understanding of patient experiences and needs, recognizing that patient perspectives are essential for informing future research and improving outcomes.
胎盘植入谱系障碍（PAS）对孕产妇健康构成重大风险，鉴于其筛查、诊断和管理的复杂性。为应对这些挑战，尤妮斯·肯尼迪·施赖弗国家儿童健康与人类发展研究所（NICHD）于2024年6月10日至11日举办了一次研讨会，召集了专业医疗保健人员、研究人员、利益相关者和患者权益倡导者，以找出知识空白，总体目标是为PAS的未来研究和最佳实践提供信息。关键讨论围绕推进PAS筛查、诊断和临床管理所需的资源和基础设施展开，同时探讨加强跨学科合作的方法。与会者考虑了优化现有研究资源的策略，并探索了加强NICHD与关键利益相关者之间伙伴关系以实现共同目标的机会。参加此次研讨会的代表来自母胎医学协会、美国妇产科医师学会、泛美胎盘植入谱系协会、国家胎盘植入基金会、美国医学超声学会和妇科肿瘤学会，旨在就PAS的重要议题达成共识，并确定PAS护理各阶段的临床和研究重点。此外，该研讨会的一个关键重点是增进对患者经历和需求的理解，认识到患者的观点对于为未来研究提供信息和改善治疗结果至关重要。
